CliffBio
biologic

Vyloy

zolbetuximab-clzb

Loss of exclusivityOctober 2036projected — 12-year biologic exclusivity estimate
CompanyAstellas Pharma Us →View the full company profile on CliffBio

Drug detail

Brand nameVyloy
Active ingredientzolbetuximab-clzb
Strength100MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2024
Marketing statusRx

More from Astellas Pharma Us

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vyloy patent cliff — loss of exclusivity October 2036 | CliffBio